PE20221663A1 - Composicion para prevenir o tratar enfermedades pulmonares que comprende proteina 1 de union de hialuronano y proteoglucano - Google Patents

Composicion para prevenir o tratar enfermedades pulmonares que comprende proteina 1 de union de hialuronano y proteoglucano

Info

Publication number
PE20221663A1
PE20221663A1 PE2022001520A PE2022001520A PE20221663A1 PE 20221663 A1 PE20221663 A1 PE 20221663A1 PE 2022001520 A PE2022001520 A PE 2022001520A PE 2022001520 A PE2022001520 A PE 2022001520A PE 20221663 A1 PE20221663 A1 PE 20221663A1
Authority
PE
Peru
Prior art keywords
composition
proteoglucan
protein
binding protein
lung diseases
Prior art date
Application number
PE2022001520A
Other languages
English (en)
Inventor
Dae Kyong Kim
Yong Wei Piao
Ji Min Jang
Dan Zhou
So Yoon Yun
Bo Kyung Park
Original Assignee
Haplnscience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Haplnscience Inc filed Critical Haplnscience Inc
Publication of PE20221663A1 publication Critical patent/PE20221663A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/314—Foods, ingredients or supplements having a functional effect on health having an effect on lung or respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Immunology (AREA)
  • Polymers & Plastics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE AL MENOS UNO SELECCIONADO DEL GRUPO QUE CONSISTE EN PROTEINA HAPLN1 (PROTEINA 1 DE UNION DE HIALURONANO Y PROTEOGLUCANO), UN GEN QUE CODIFICA LA PROTEINA HAPLN1 Y UN AGENTE EFICAZ PARA POTENCIAR LA EXPRESION O ACTIVAR LAS FUNCIONES DE LA PROTEINA O DEL GEN HAPLN1 COMO PRINCIPIO ACTIVO; DONDE LA PROTEINA HAPLN1 COMPRENDE UNA SECUENCIA DE AMINOACIDOS QUE TIENE AL MENOS UN 95 % DE IDENTIDAD DE SECUENCIA CON SEQ ID NO: 1. DICHA COMPOSICION ES UTIL EN EL TRATAMIENTO DE ENFERMEDADES PULMONARES COMO BRONQUITIS CRONICA, ASMA, ENFISEMA, ENFERMEDAD PULMONAR OBSTRUCTIVA CRONICA (EPOC).
PE2022001520A 2020-02-03 2021-02-02 Composicion para prevenir o tratar enfermedades pulmonares que comprende proteina 1 de union de hialuronano y proteoglucano PE20221663A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020200012742A KR102166453B1 (ko) 2020-02-03 2020-02-03 Hapln1을 포함하는 폐질환 예방 또는 치료용 조성물
PCT/KR2021/001374 WO2021158000A1 (en) 2020-02-03 2021-02-02 Composition for preventing or treating pulmonary diseases comprising hyaluronan and proteoglycan link protein 1

Publications (1)

Publication Number Publication Date
PE20221663A1 true PE20221663A1 (es) 2022-10-26

Family

ID=72882981

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2022001520A PE20221663A1 (es) 2020-02-03 2021-02-02 Composicion para prevenir o tratar enfermedades pulmonares que comprende proteina 1 de union de hialuronano y proteoglucano

Country Status (17)

Country Link
US (1) US12268728B2 (es)
EP (1) EP3887525B1 (es)
JP (1) JP7329877B2 (es)
KR (1) KR102166453B1 (es)
CN (1) CN115427576B (es)
AR (1) AR121243A1 (es)
AU (1) AU2021216358A1 (es)
BR (1) BR112022015361A2 (es)
CA (1) CA3166146A1 (es)
CL (1) CL2022002067A1 (es)
CO (1) CO2022011135A2 (es)
ES (1) ES2964715T3 (es)
IL (1) IL294952A (es)
MX (1) MX2022009544A (es)
PE (1) PE20221663A1 (es)
TW (1) TWI792171B (es)
WO (1) WO2021158000A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102166453B1 (ko) 2020-02-03 2020-10-15 중앙대학교 산학협력단 Hapln1을 포함하는 폐질환 예방 또는 치료용 조성물
KR102284800B1 (ko) 2020-12-30 2021-08-03 주식회사 하플사이언스 재조합 세포외 기질 단백질의 생산을 위한 동물세포 배양용 배지 조성물 및 이를 이용한 방법
KR102678583B1 (ko) * 2021-05-31 2024-06-27 중앙대학교 산학협력단 Hapln1을 포함하는 혈관질환 예방 또는 치료용 조성물

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS584462Y2 (ja) 1980-10-13 1983-01-25 古賀産業株式会社 海苔「す」
KR100785969B1 (ko) 2004-05-12 2007-12-14 동아제약주식회사 Ｆｇｆ2를 유효성분으로 포함하는 천식 및 만성폐쇄성폐질환 예방 또는 치료제
MX2007000625A (es) 2004-07-16 2007-03-07 Warner Lambert Co Agentes activadores del crecimiento capilar.
GB0422525D0 (en) 2004-10-11 2004-11-10 Luebcke Peter Dermatological compositions and methods
WO2007027509A2 (en) 2005-08-31 2007-03-08 Biogen Idec Ma Inc. Evaluating and treating scleroderma
US7908090B2 (en) 2005-11-30 2011-03-15 The Board Of Trustees Of The Leland Stanford Junior University Signatures for human aging
US20080139500A1 (en) 2006-12-11 2008-06-12 Isadore Elliott Goldberg Use of composite monomer or monomers, catalyst, sodium hyaluronate or hyaluronic acid, glucosamide sulfate, chondroiten sulfate or chlorides, for the treatment of osteoarthritis by intraarticular application to a hip or knee joint
RU2631488C2 (ru) 2009-07-10 2017-09-22 Хистоджен, Инк. Кондиционированная среда и композиции на основе внеклеточного матрикса из клеток, культивированных в гипоксических условиях
KR101704666B1 (ko) 2009-07-16 2017-02-08 바이오타임, 인코포레이티드 시험관내 및 생체내 연골형성을 위한 방법 및 조성물
US20120128632A1 (en) 2009-07-23 2012-05-24 Jeffrey Keeler Teumer Identity markers
US8334136B2 (en) 2009-07-24 2012-12-18 Shiseido Company, Ltd. Method for promoting hair growth or hair regeneration by maintaining or increasing expression of cell-adhesion factor
EP2552472A4 (en) 2010-03-29 2014-03-12 Massachusetts Inst Technology INFLAMMATION INHIBITING FACTORS
EP2704728A4 (en) 2011-05-03 2015-04-22 Dermachip Inc EXPRESSION SIGNATURES OF AGENTS ASSOCIATED WITH SKIN AGING AND GEN NETWORKS
JP6043343B2 (ja) 2011-05-17 2016-12-14 シャネル パフュームズ ビューテ 皮膚の老化の予防および／もしくは低減ならびに／または皮膚を水和するためのｌａｒｇｅ、ｈｓ６ｓｔ２またはｓｔ８ｓｉａ１活性化剤
JP6162707B2 (ja) * 2011-10-24 2017-07-12 ハロザイム インコーポレイテッド 抗ヒアルロナン剤治療のためのコンパニオン診断およびその使用方法
JP5767591B2 (ja) 2012-01-24 2015-08-19 ＨＯＹＡ Ｔｅｃｈｎｏｓｕｒｇｉｃａｌ株式会社 人工軟骨の製造方法
WO2013129456A1 (ja) 2012-02-29 2013-09-06 ロート製薬株式会社 線維芽細胞増殖促進能を有する組成物
WO2013144672A1 (en) 2012-03-30 2013-10-03 Société De Développement Et De Recherche Industrielle Method and kit for the classification and prognosis of wounds
EP2845910A4 (en) 2012-05-02 2015-11-25 Mitsubishi Rayon Co PROBE OR PROBE TO EVALUATE THE INFLUENCE OF ULTRAVIOLET RADIATION ON SKIN AND NUCLEIC ACID MICRO ARRAYS
US10245229B2 (en) * 2012-06-08 2019-04-02 Translate Bio, Inc. Pulmonary delivery of mRNA to non-lung target cells
JP2015528001A (ja) * 2012-07-11 2015-09-24 ティッシュテック，インク． Ｈｃ−ｈａ／ｐｔｘ３複合体を含む組成物およびその使用方法
AU2013237760A1 (en) 2012-10-08 2014-04-24 Biotime, Inc. Differentiated progeny of clonal progenitor cell lines
WO2014130411A1 (en) 2013-02-22 2014-08-28 Emory University Tgf-beta enhancing compositions for cartilage repair and methods related thereto
US20160192689A1 (en) 2013-07-31 2016-07-07 Wikifoods, Inc. Encapsulated functional food compositions
US11819555B2 (en) 2013-09-09 2023-11-21 Figene, Llc Gene therapy for the regeneration of chondrocytes or cartilage type cells
JP6538081B2 (ja) 2014-07-07 2019-07-03 メディポスト カンパニー リミテッド 刺激を受けた幹細胞の馴化培地の発毛促進能およびそれらの使用
HUE053684T2 (hu) 2015-01-07 2021-07-28 Pfizer Oldható FGFR3 csalik csontnövekedési rendellenességek kezelésére
GB201505520D0 (en) 2015-03-31 2015-05-13 Univ Lancaster Composition
KR101897340B1 (ko) * 2015-09-09 2018-09-13 중앙대학교 산학협력단 Hapln1을 이용한 피부 노화 측정 또는 예방 또는 개선용 조성물
AU2017207445B2 (en) 2016-01-14 2023-12-07 Spinalcyte, Llc Cellular blend for the regeneration of chondrocytes or cartilage type cells
KR101900748B1 (ko) 2016-08-17 2018-09-20 (주)진셀팜 모발 성장 촉진 효과를 가지는 펩타이드, 및 이의 용도
CA3055168C (en) * 2017-03-06 2022-09-06 Haplnscience inc. Composition for skin aging measurement, prevention, or alleviation using hapln1
KR20190024727A (ko) 2017-08-29 2019-03-08 중앙대학교 산학협력단 Hapln1을 유효성분으로 함유하는 연골 재생용 조성물
WO2019045451A1 (ko) 2017-08-29 2019-03-07 중앙대학교 산학협력단 Hapln1을 유효성분으로 함유하는 연골 재생용 조성물
KR20200104831A (ko) 2019-02-27 2020-09-04 주식회사 하플사이언스 Hapln1을 포함하는 연골 관련 질환 또는 증상의 예방, 개선 또는 치료용 조성물
MX2021008327A (es) 2019-02-28 2021-08-11 Haplnscience Inc Composicion para prevenir, mejorar o tratar enfermedades o sintomas relacionados con el cartilago que comprende hapln1.
AU2020265476A1 (en) 2019-04-30 2022-01-06 Haplnscience inc. Composition for prevention or treatment of hair loss including HAPLN1
KR102166453B1 (ko) 2020-02-03 2020-10-15 중앙대학교 산학협력단 Hapln1을 포함하는 폐질환 예방 또는 치료용 조성물
KR102284800B1 (ko) 2020-12-30 2021-08-03 주식회사 하플사이언스 재조합 세포외 기질 단백질의 생산을 위한 동물세포 배양용 배지 조성물 및 이를 이용한 방법

Also Published As

Publication number Publication date
JP2022524899A (ja) 2022-05-11
AU2021216358A1 (en) 2022-09-01
MX2022009544A (es) 2022-08-25
CA3166146A1 (en) 2021-08-12
BR112022015361A2 (pt) 2022-09-20
CN115427576B (zh) 2025-02-28
US20220305077A1 (en) 2022-09-29
IL294952A (en) 2022-09-01
CN115427576A (zh) 2022-12-02
EP3887525A4 (en) 2022-06-22
WO2021158000A1 (en) 2021-08-12
EP3887525A1 (en) 2021-10-06
TWI792171B (zh) 2023-02-11
EP3887525B1 (en) 2023-08-23
ES2964715T3 (es) 2024-04-09
JP7329877B2 (ja) 2023-08-21
AR121243A1 (es) 2022-05-04
TW202130360A (zh) 2021-08-16
CL2022002067A1 (es) 2023-01-20
US12268728B2 (en) 2025-04-08
EP3887525C0 (en) 2023-08-23
CO2022011135A2 (es) 2022-08-30
KR102166453B1 (ko) 2020-10-15

Similar Documents

Publication Publication Date Title
PE20221663A1 (es) Composicion para prevenir o tratar enfermedades pulmonares que comprende proteina 1 de union de hialuronano y proteoglucano
AR068767A1 (es) Anticuerpos contra esclerostina, composiciones y metodos de uso de estos anticuerpos para tratar un trastorno patologico mediado por esclerostina
MX2021015753A (es) Constructo de arn.
PE20190352A1 (es) Proteinas de fusion gdf 15 y usos de estas
PE20191614A1 (es) Anticuerpo humanizado para tratar o prevenir trastornos cognitivos, proceso para producirlo, y agente para tratar o prevenir trastornos cognitivos usandolo
CL2019003404A1 (es) Péptido asociados a tumor (tumap) aislado; ácido nucleico; vector de expresión; célula huésped recombinante que comprendes el péptido; método para producir el péptido; uso para preparar un medicamento útil rara tratar el cáncer; kit farmacéutico.(divisional solicitud 201702407)
MX2022010175A (es) Proteinas de union a flt3 y metodos de uso.
MX2020009856A (es) Rimegepant para trastornos relacionados con el peptido relacionado con el gen para calcitonina (cgrp).
BR112018068189A2 (pt) proteínas de ligação induzíveis e métodos de uso
BR112021021224A2 (pt) Anticorpos ou fragmentos de anticorpos, composição farmacêutica, kit, ácido nucleico ou conjunto de ácidos nucleicos, célula hospedeira recombinante e método para o tratamento ou a prevenção de uma doença em um paciente em necessidade do mesmo
PE20190911A1 (es) Composiciones y anticuerpos anti-lag-3
BR112021019520A2 (pt) Composição farmacêutica, método para tratar a síndrome de hunter e uso de uma composição farmacêutica
PE20191203A1 (es) Variantes de alfa-glucosidasa acida y usos de las mismas
PE20190420A1 (es) Proteinas f de prefusion del virus respiratorio sincicial (vrs) solubles y estabilizadas
PE20140867A1 (es) Axmi-115, axmi-113, axmi-005, axmi-163 y axmi-184: proteinas insecticidas y metodos para su uso
PE20141727A1 (es) Composiciones, usos y metodos para tratamiento de trastornos y enfermedades metabolicas
MX2022013945A (es) Nuevas proteinas de union a repeticiones de anquirina y sus usos.
WO2011036442A3 (en) Thrombin c- terminal polypeptides and uses thereof for treating inflammation coagulation disorders
MX2019008949A (es) Agente terapeutico para cardiomiopatia, infarto al miocardio antiguo e insuficiencia cardiaca cronica.
BR112021015751A2 (pt) Vetores de terapia genética para tratamento da doença de danon
BR112022022503A2 (pt) Anticorpos neutralizantes que se ligam à proteína s de sars-cov-2
AR095076A1 (es) Péptidos y composiciones para el tratamiento de daño articular
PE20180509A1 (es) Composiciones y metodos para tratar la enfermedad celiaca
BR112015020439A2 (pt) material de substituição óssea para a cirurgia óssea e dentária e processo de preparação de um material de substituição óssea
BR112021024997A2 (pt) Anticorpos, polinucleotídeo, vetor de expressão, célula hospedeira, composição farmacêutica, métodos e uso